On December 28 2023, Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. (TSE: 4503) announced a research collaboration and license agreement for novel bi-specific macrophage engagers（BiME^®;），ES019 and another program. The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program.

In January 2021 we entered into an exclusive licensing agreement with TRIGR Therapeutics, now part of Compass Therapeutics, for the development, manufacture and commercialization of ES104/TR009, an investigational bispecific antibody targeting VEGF and DLL4, in China.

We have two partnered programs with Inhibrx, a bispecific antibody targeting 4-1BB and PD-L1 (ES101/INBRX-105) and an agonistic OX40 antibody (ES102/INBRX-106) in greater China.

In May 2020 we entered a clinical collaboration with Junshi Biosicences to evaluate the safety, tolerability and potential early efficacy signal of ES102, a next generation OX40 agonistic antibody, in combination with toripalimab (TUOYI®), an anti-PD-1 mAb and immune checkpoint inhibitor for the treatment of patients with advanced solid tumors and hematological tumors.